-
Advanced Medical Weight Loss
Precision Care. Real Results.
Wegovy® • Zepbound® • Daily Oral Options
The Future of Weight Loss: Medication Pipeline
A look at the investigational Anti-Obesity Medications (AOMs) currently in clinical trials.
Clinical Note: The medications listed below are Investigational Only. They are not yet FDA-approved or available for prescription. This page serves as an educational resource on the future of Obesity Medicine.
While Wegovy® and Zepbound® have revolutionized medical weight loss, the research pipeline is overflowing with even more potent and convenient options. As a leading Obesity Medicine clinic, Clinical Nutrition Center closely monitors Phase 2 and Phase 3 clinical trials to prepare for the next generation of therapies.
1. The “Triple Agonists” (Retatrutide)
If Ozempic® is a single instrument and Zepbound is a duet, Retatrutide is a trio. It mimics three different hormones simultaneously:
- GLP-1: Controls satiety and insulin.
- GIP: Improves fat metabolism.
- Glucagon: Increases energy expenditure (calorie burning) in the liver.
Status: Phase 3 Trials. Early data suggests weight loss approaching 24-26%, which is comparable to bariatric surgery results.
2. Next-Gen Oral Medications
The current challenge with peptides (like Wegovy®) is that they are hard to manufacture and mostly injectable. The future is “Small Molecule” oral drugs that are easier to produce and take as a daily pill.
Orforglipron (Eli Lilly)
Mechanism: Oral GLP-1 Agonist (Non-peptide).
Unlike the current Oral Wegovy® pill which has strict fasting rules, Orforglipron is a small molecule that may offer more flexible dosing and similar potency.
Amycretin (Novo Nordisk)
Mechanism: Oral GLP-1 + Amylin Agonist.
Early Phase 1 data showed incredible promise, with patients losing ~13% body weight in just 12 weeks. In a single pill, it targets both the GLP-1 pathway and Amylin, a pancreatic hormone that signals fullness.
3. Combination Therapies (CagriSema)
CagriSema is a combination of two drugs in one injection:
- Semaglutide: The active ingredient in Wegovy.
- Cagrilintide: A long-acting Amylin analog.
Why it matters: By hitting two completely different hunger pathways, this combination aims to break the “plateaus” patients often see with semaglutide alone. Head-to-head trials suggest it outperforms Wegovy significantly, and potentially offers improved retention of lean body weight during weight loss.
4. Liver-Focused Agents (Survodutide)
Survodutide is a dual agonist (GLP-1 + Glucagon). While it produces significant weight loss, it is generating excitement for its potential to treat MASH (Metabolic Dysfunction-Associated Steatohepatitis), a serious fatty liver disease often linked with obesity.
5. High-Dose Formulations
Manufacturers are investigating whether higher doses of current drugs can yield better results. Novo Nordisk has submitted to have high dose Wegovy 7.2 mg weekly approved (compared to the current maximum dose of 2.4 mg). The new formulation provides higher percent body weight loss than existing drugs. In addition, studies are looking at High-Dose Oral Semaglutide (up to 50 mg, compared to the current 25 mg limit of Oral Wegovy) to see if it can match the efficacy of injections.
Should You Wait for These Drugs?
No. Obesity is a progressive disease. Waiting 2-3 years for FDA approval allows the disease to progress.
The best strategy is to treat your biology now with currently approved options like Wegovy®, Zepbound®, or Oral Meds. If a superior drug is approved in the future, our physicians can transition you to the new therapy immediately.